Piper Sandler raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $51 from $35 and keeps an Overweight rating on the shares. The firm says that the company’s CRB-701 continues to look meaningfully active in heavily pre-treated HNSCC and cervical cancers in its Phase 1/2 ESMO update, with ORR of 48% in HNSCC and 38% in cervical at the 3.6 mg/kg dose – meaningfully higher than the bar set by Merus’ petosemtamab in HNSCC and Tivdak in cervical.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Promising Trial Results and Market Potential Drive Buy Rating for Corbus Pharmaceuticals’ CRB-701
- Promising Potential of Corbus Pharmaceuticals’ CRB-701: A Best-in-Class ADC with Strong Safety and Efficacy
- Corbus Pharmaceuticals presents CRB-701 clinical responses at ESMO25
- Corbus Pharmaceuticals’ Promising CRB-701 Trial and Strategic Investor Engagement Justify Buy Rating
- Corbus Pharmaceuticals to present CRB-701 Phase 1/2 data at ESMO 2025